Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection
| Autor: | Saleem E. Noormohamed, Keith Henry, Richard C. Brundage, Peter L. Anderson, Henry H. Balfour, Courtney V. Fletcher |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Adolescent Anti-HIV Agents Physiology Semen HIV Infections Asymptomatic Zidovudine Glucuronides Pharmacokinetics Oral administration medicine Humans Pharmacology (medical) business.industry Area under the curve Pharmacodynamics Area Under Curve Immunology HIV-1 Viral disease medicine.symptom business medicine.drug |
| Zdroj: | Pharmacotherapy. 20(8) |
| ISSN: | 0277-0008 |
| Popis: | Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0–48:serum AUC0–∞) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text